biomodal, formerly known as Cambridge Epigenetix, has launched its new duet multiomics solution, which it says reveals the combinatorial power of genetic and epigenetic information from a single low-volume sample.
The duet multiomics solution is the world’s first single-base resolution sequencing technology that enables simultaneous step-by-step reading of genetic and epigenetic information in a single sample, with a single workflow, using any sequencer.
Hardware-agnostic products provide more epigenetic information from low-input DNA libraries without complex, resource-intensive bioinformatics or harsh chemical treatments.
Recently published in Nature Biotechnology, the solution provides a more complete picture of the information stored in the genome leveraging new insights from biomedical-wide applications.
“Our new solution removes technical barriers that previously held back our broader understanding of epigenetics. Now, our customers can accelerate their research with a more comprehensive view of regulatory function across the genome, through genetic and epigenetic interactions at the read level. We believe this opens a new era of discovery and utility in next-generation sequencing by capturing additional biological modalities to unravel the complexity and dynamism of the human genome,” said Peter Fromen, CEO of biomodal.
Duet’s multiomics solutions empower applications in many areas of disease research, providing broader biological insights into cancer, neurodegenerative diseases, aging, cell biology and population genetics. Using cell-free DNA via liquid biopsy, multiomics duet can simultaneously detect strong genetic and methylation biomarkers in a person’s blood to provide unique disease insights.
In particular, the use of liquid biopsies in oncology, to profile circulating tumor DNA (ctDNA) in the blood, is a promising minimally invasive approach for early detection of cancer and monitoring of minimal residual disease.
“The duet + modC multiomic solution helps unlock the full potential of liquid biopsies by breaking down a significant barrier in our biomarker discovery research, which relies on obtaining accurate and comprehensive genetic and epigenetic data from our valuable samples,” said Sarah-Jane Dawson, physician-scientist at the Peter MacCallum Cancer Center.
“We gain new insights when measuring genetic and epigenetic interactions on the same readout, enabling us to better understand the biology behind disease development and treatment response. We look forward to advancing our research with this technology and influencing a paradigm shift in the way cancer is treated and monitored in the clinic.”
This technology has been designed with accessibility at its core and is compatible with existing sequencers.
The first duet multiomic solution, +modC, allows sequencing of all DNA canonical bases (A,C,G,T), plus the modified cytosine via one low input sample (10ng). The plug-and-play software solution combines open source and proprietary tools to form a seamless analysis pipeline that combines error suppression, generating high-quality data on a base call over Q40. Sample-level information is then ready for interpretation and insight via our proprietary analytics module.
This means customers can integrate the technology into their existing workflows without first having to buy new hardware or build new bioinformatics tools.